Panel: Biotech’s Capital Gambit: IPOs, Private Paths and the Road Ahead

Session details:

The public markets have remained largely shuttered to biotech companies throughout 2025, forcing a fundamental recalculation of growth strategies across the sector. While private funding has provided a lifeline, the question looms: are companies positioning for eventual public debuts or recalibrating toward longer-term private paths? This panel will examine the strategic calculus behind capital structure decisions and whether market conditions are aligning for a meaningful reopening of the IPO window.